SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-077217
Filing Date
2022-03-16
Accepted
2022-03-16 16:01:33
Documents
15
Period of Report
2022-03-16
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d223867d8k.htm   iXBRL 8-K 32062
5 GRAPHIC g223867g02a02.jpg GRAPHIC 99970
6 GRAPHIC g223867g02a03.jpg GRAPHIC 64473
7 GRAPHIC g223867g05x05.jpg GRAPHIC 47206
  Complete submission text file 0001193125-22-077217.txt   705847

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA apls-20220316.xsd EX-101.SCH 2858
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE apls-20220316_lab.xml EX-101.LAB 17237
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apls-20220316_pre.xml EX-101.PRE 10814
9 EXTRACTED XBRL INSTANCE DOCUMENT d223867d8k_htm.xml XML 3202
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

IRS No.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38276 | Film No.: 22744829
SIC: 2834 Pharmaceutical Preparations